drug
dexamethasone LA
Marketedupdated 6mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.
indications
investigational
Diabetic Macular Edema
all catalysts(14)
approval · 14
Jun 17, 2009
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Aug 31, 2010
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 24, 2010
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 24, 2012
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 7, 2012
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 7, 2014
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Jun 28, 2014
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 26, 2014
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 5, 2016
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
May 15, 2018
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Oct 21, 2020
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Dec 19, 2022
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Mar 11, 2026
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
TBD
approval
$ABBV294.55-0.16%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Trials studying dexamethasone LA
- phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
- phase4Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
- phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 7, 2028
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 26, 2041method-of-use (U-1680)US 12144889
- Jun 23, 2039formulationUS 11097061
- Nov 16, 2037method-of-use (U-3455)US 11458041
- Oct 7, 2036method-of-use (U-3455)US 12150896
- Jun 22, 2034method-of-use (U-2340)US 10022502
- May 23, 2034method-of-use (U-2340)US 10028965
- May 23, 2034formulationUS 10159683
- May 11, 2032formulationUS 10799642
- May 14, 2030formulationUS 84096063.5y
- Feb 12, 2030method-of-use (U-2487)US 85630273.2y
FDA exclusivities (1)
- Apr 7, 2028NPPNew Product (3y)1.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that